The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

A recent study found that combined tocilizumab and glucocorticoid therapy for at least 6 months did not fully eliminate ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...

NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

Testosterone worsens the damage caused by a heart attack by increasing the number of white blood cells released from the bone marrow. This is shown in a study by the University of Gothenburg, Sweden.

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

Testosterone worsens the damage caused by a heart attack by increasing the number of white blood cells released from the bone ...